MCP110 is primarily used in research settings as a potent inhibitor of the MDM2-p53 protein-protein interaction. By disrupting this interaction, MCP110 activates the p53 tumor suppressor pathway, making it a valuable tool in cancer research. It is especially useful in studies focused on inducing apoptosis in tumor cells that overexpress MDM2. Due to its ability to cross the blood-brain barrier, MCP110 is also explored in models of brain cancers and neurodegenerative diseases where p53 modulation may play a therapeutic role. Its application extends to in vitro and in vivo studies to evaluate tumor growth suppression and to understand the dynamics of p53 activation in cellular stress responses.